Gilead Sciences, Inc. vs Regents of the University of Minnesota

CAFC Mandate

CAFC Opinion

Patent Owner's Notice of Appeal

Termination Decision Document

Hearing Transcript

Patent Owner's Objections to Petitioner's Demonstrative Exhibits

Patent Owner's Demonstrative Exhibits

Patent Owner's Notice of Filing Demonstrative Exhibits

Petitioner's Demonstrative Exhibits

Petitioner's Updated Exhibit List

Petitioner's Objections to Patent Owner's Demonstrative Exhibits

Order - Setting Oral Argument - 37 CFR 42.70

Patent Owner's Request for Oral Hearing

Petitioner's Request for Oral Argument

Wattanasin v. Fujikawa, Interference 102,648, Paper 119 (BPAI Jan. 31, 1995)

Patent Owner's Sur-Reply to Gilead's Reply

Petitioner's Reply

Judith Howard et al., How Good is Fluorine as a Hydrogen Bond Acceptor?, Tetrahedron 52(38):12613-22 (1996)

World Intellectual Property Organization (WIPO) FAQs: Amendments to the PCT Regulations (April 1, 2007)

Transcript of the October 8, 2020 Deposition of Dr. Andrea Brancale

Second Declaration of Dr. Gerardus Josephus Petrus Henricus Boons

Florante A. Quiocho, Protein-carbohydrate interactions: basic molecular features, Pure & Appl. Chem. 61(7):1293-1306 (1989)

Petitioner's Sixth Amended Mandatory Notices

Notice of Deposition of Dr. Andrea Brancale

Balzarini et al., Antiretrovirus Specificity and Intracellular Metabolism of 2',3'-Didehydro-2',3'-Dideoxythymidine (Stavudine) and Its 5'-Monophosphate Triester Prodrug So324, 50(5) MOLECULAR PHARMACOLOGY 1207-13 (1996) ("Balzarini 1996")

Abraham et al., Synthesis and Biological Activity of Aromatic Amino Acid Phosphoramidates of 5-Fluoro-2'-Deoxyuridine and 1-Beta-Arabinofuranosylcytosine: Evidence of Phosphoramidase Activity, 39(23) J. MED. CHEM. 4569-75 (1996) ("Abraham 1996")

Marquez et al., HIV-1 Reverse Transcriptase Can Discriminate between Two Conformationally Locked Carbocyclic AZT Triphosphate Analogues, 120 J. AM. CHEM. SOC. 2780-89 (1998) ("Marquez 1998")

Brenner et al., Crystal structures of HINT demonstrate that histidine triad proteins are GalT-related nucleotide-binding proteins, 4(3) NATURE STRUCTURAL BIOLOGY 231-38 (1997) ("Brenner 1997")

Lima et al., Structure-Based Analysis of Catalysis and Substrate Definition in the HIT Protein Family, 278(5336) SCIENCE 286-90 (1997) ("Lima 1997")

Chang et al., Amino Acid Phosphoramidate Monoesters of 3'-Azido-3'-Deoxythymidine: Relationship Between Antiviral Potency and Intracellular Metabolism, 44(2) J. MED. CHEM. 223-31 (2001) ("Chang 2001")

Carroll et al., Inhibition of Hepatitis C Virus RNA Replication by 2'- Modified Nucleoside Analogs, 278(14) J. BIO. CHEM. 11979-84 (2003) ("Carroll 2003")

Marquez et al., Experimental and Structural Evidence that Herpes 1 Kinase and Cellular DNA Polymerase(s) Discriminate on the Basis of Sugar Pucker, 126(2) J. AM. CHEM. SOC. 543-49 (2004) ("Marquez 2004")

Eldrup et al., Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase, 47(9) J. MED. CHEM. 2283-95 (2004) ("Eldrup 2004")

De Clercq, Antivirals and Antiviral Strategies, 2(9) NATURE REVIEWS MICROBIOLOGY 2(9):704-20 (2004) ("De Clercq 2004")

Kim et al., Monitoring the Intracellular Metabolism of Nucleoside Phosphoramidate Pronucleotides by 31P NMR, 23(1-2) NUCLEOSIDES NUCLEOTIDES NUCLEIC ACIDS 483-93 (2004) ("Kim 2004")

De Clercq, Antivirals and Antiviral Strategies (Supplementary Information), 2(9) NATURE REVIEWS MICROBIOLOGY 704-20 (2004) ("De Clercq 2004 Supplemental Information")

U.S. Patent Publication No. 2005/0009737 ("Clark")

Clark et al., Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine, a Potent Inhibitor of Hepatitis C Virus Replication, 48(14) J. MED. CHEM. 5504-08 (2005) ("Clark 2005")

Chou et al., 31P NMR and Genetic Analysis Establish hinT as the Only Escherchia coli Purine Nucleoside Phosphoramidase and as Essential for Growth under High Salt Conditions, 280(15) J. BIO. CHEM. 15356-61 (2005) ("Chou 2005")

Sofia et al., Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase, 55(6) J. MED. CHEM. 2481-2531 (2012) ("Sofia 2012")

U.S. Patent No. 6,475,985 ("the '985 Patent")

U.S. Patent No. 7,951,787 ("the '787 Patent")

Perrone et al., First Example of Phosphoramidate Approach Applied to a 4'-Substituted Purine Nucleoside (4'-Azidoadenosine) 50(22) J. MED. CHEM. 5463-5470 (2007) ("Perrone 2007")

Murakami et al., Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977, 285(45) J. BIO. CHEM. 34337¿¿¿47 (2010) ("Murakami 2010")

Sofia, M.J., Nucleotide prodrugs for HCV therapy, 22(1) ANTIVIRAL CHEMISTRY & CHEMOTHERAPY 23-49 (2011) ("Sofia 2011")

Drontle et al., Designing a Pronucleotide Strategem: Lessons from Amino Acid Phosphoramidates of Anticancer and Antiviral Pyrimidines, 4(4) MINI-REVS. IN MED. CHEM. 409-19 (2004) ("Drontle 2004")

Chou et al., Phosphoramidate Pronucleotides, MOLECULAR PHARMS. 208-17 (2007) ("Chou 2007, Phosphoramidate Pronucleotides")

U.S. Patent No. 4,303,796

Petition for Inter Partes Review, IPR2018-00119 (Filed October 25, 2017)

Chu, C. K., Chapter 1: Recent Advances in Antiviral Nucleosides, in ANTIVIRAL NUCLEOSIDES: CHIRAL SYNTHESIS AND CHEMOTHERAPY, 1-76 (2003) ("Chu 2003")

Glick and Pasternak, Chapter 3: DNA, RNA, and Protein Synthesis, in MOLECULAR BIOTECHNOLOGY, PRINCIPLES AND APPLICATIONS OF RECOMBINANT DNA 19-44 (2d ed. 1998) ("Glick 1998")

Loudon, G.M., ORGANIC CHEMISTRY, excerpts (3rd ed. 1995) ("Loudon 1995") Part 1 of 2

Dressman et al., Upper Gastrointestinal (GI) pH in Young, Healthy Men and Women, 7 PHARM. RSCH. 756-61 (1990) ("Dressman 1990")

McGuigan et al., Phosphoramidate Derivatives of d4T as Inhibitors of HIV: The Effect of Amino Acid Variation, 35 ANTIVIRAL RSCH. 195-204 (1997) ("McGuigan 1997")

Dudkin et al., Hydrolysis of Uridine-5' N-aryl and N-alkyl Phosphoramidates by Ribonucleoside-5' Phosphoramidase, 16(1) FEBS LETTERS 48-50 (1971) ("Dudkin 1971")

Abraham et al., Synthesis, Biological Activity and Decomposition Studies of Amino Acid Phosphomonoester Amidates of Acyclovir, 16(10-11) NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS 2079-92 (1997) ("Abraham 1997")

Ippolito et al., Hydrogen Bond Stereochemistry in Protein Structure and Function, 215(3) J. MOLECULAR BIO. 457-71 (1990) ("Ippolito 1990")

U.S. Patent No. 7,964,580 ("the '580 Patent")

U.S. Provisional Application No. 60/909,315 (¿¿¿Sofia Provisional¿¿¿)

Boons et al., ORGANIC SYNTHESIS WITH CARBOHYDRATES (Sheffield Acad. Press. 2000) ("Boons 2000")

Petition for Inter Partes Review, IPR2017-02005 (Filed August 29, 2017)

Idenix Pharms. v. Gilead Scis. (2014) (UK) ¿¿¿ Transcript of Proceedings Day 4 ("Boons UK Testimony")

Idenix Pharms. v. Gilead Scis. (2014) (UK) ¿¿¿ Transcript of Proceedings Day 5

Chou et al., Evidence that Human Histidine Triad Nucleotide Binding Protein 3 (Hint3) Is a Distinct Branch of the Histidine Triad (HIT) Superfamily, 373(4) J. MOLECULAR BIO. 978-89 (2007) ("Chou 2007, Hint3")

International Publication No. WO 2006/063149

Declaration of Dr. Andrea Brancale ("Brancale")

Curriculum Vitae of Dr. Andrea Brancale

De Clercq, In Search of a Selective Antiviral Chemotherapy, 4(10) CLINICAL MICROBIO. REVS. 674-93 (1997) ("De Clercq 1997")

Field et al., Antiviral Drugs ¿¿¿ A Short History of Their Discovery and Development, 31 MICROBIO. TODAY 58-61 (2004) ("Field 2004")

Wagner et al., Pronucleotides: Toward the In Vivo Delivery of Antiviral and Anticancer Nucleotides, 20(6) MEDICINAL RESEARCH REVIEWS 417-51 (2000) ("Wagner 2000")

Kremer, Cytarabine, 82 ANNALS OF INTERNAL MED. 684-88 (1975) ("Kremer 1975")

Hui et al., Gemcitabine: A Cytidine Analogue Active Against Solid Tumors, 84 AM. J. HEALTH-SYST. PHARM. 162-170 (1997) ("Hui 1997")

Voet and Voet, BIOCHEMISTRY, excerpts (2d ed. 1995) ("Voet 1995")

De Clercq, E., Strategies in the Design of Antiviral Drugs, 1 NATURE REVS. DRUG DISCOVERY 13-25 (2002) ("De Clercq 2002")

Loudon, G.M., ORGANIC CHEMISTRY, excerpts (3rd ed. 1995) ("Loudon 1995") Part 2 of 2

Guschlbauer et al., Nucleoside Conformation Is Determined by the Electronegativity of the Sugar Substituent, 8(6) NUCLEIC ACIDS RESEARCH 1421-33 (1980) ("Guschlbauer 1980")

Mundy, Armold, and Amend, ORGANIC AND BIOLOGICAL CHEMISTRY R1-16 (1993) ("Mundy 1993")

Abraham et al., A Phosphoramidite-Based Synthesis of Phosporamidate Amino Acid Deisters of Antivrial Nucleosides, 13 NECLEOSIDES AND NUCLEOTIDES 1891-1903 (1994) ("Abraham 1994")

McGuigan et al., Phosphoramidate as Potent Prodrugs of Anti-HIV Nucleotides: Studies in the Amino Region, 7(1) ANTIVIRAL CHEM. AND CHEMOTHERAPY 31-36 (1996) ("McGuigan 1996")

Bieganowski et al., Adenosine Monophosphoramidase Activity of Hint and Hnt1 Supports Function of Kin28, Ccl1, and Tfb3, 277(13) J. BIO. CHEM. 10852-60 (2002) ("Bieganowski 2002")

U.S. Provisional Application No. 60/584,958

"1KPE, PKCI-Transition State Analog" PROTEIN DATA BANK, https://www.rcsb.org/structure/1KPE, (last accessed August 19, 2020)

Dolot et al., A new crystal form of human histidine triad nucleotide-binding protein 1 (hHINT1) in complex with adenosine 500-monophosphate at 1.38A resolution, in ACTA CRYSTALLOGRAPHICA SECTION F: STRUCTURAL BIO. COMM'NS. 883-88 (2012) ("Dolot 2012")

Prevost et al., Synthesis of 1',2'-cis-Nucleoside Analogues: Evidence of Stereoelectronic Control for SN2 Reactions at the Anomeric Center of Furanosides, 132(35) J. AM. CHEM. SOC.12433-39 (2010) ("Prevost 2010")

Praly et al., Influence of solvent on the magnitude of the anomeric effect, 65 CANADIAN J. CHEM. 213-223 (1986) ("Praly 1986")

McGuigan et al., Synthesis and evaluation of some novel phosphoramidate derivatives of 3'-azido-3'deoxythymidine (AZT) as anti-HIV compounds, 1(2) ANTIVIRAL CHEM. & CHEMOTHERAPY 107-113 (1990) ("McGuigan 1990")

U.S. Patent No. 7,429,572

U.S. Patent Publication No. 2006/0142238 ("McGuigan '238 Publication")

Plavec et al., How Do the Gauche and Anomeric Effects Drive the Pseudorotational Equilibrium of the Pentofuranose Moiety of Nucleosides? 115 J. AM. CHEM. SOC 9734-46 (1993) ("Plavec 1993")

Hammen et al., Investigation of a side-chain-side-chain hydrogen bond by mutagenesis, thermodynamics, and NMR spectroscopy, 4(5) PROTEIN SCIENCE 936-44 (1995) ("Hammen 1995")

Fox & Powell, NOMENCLATURE OF ORGANIC COMPOUNDS: PRINCIPLES AND PRACTICE 337-343 (2d ed. 2001) ("Fox 2001")

Venkatachalam et al., Rational Drug Design of Multifunctional Phosphoramidate Substituted Nucleoside Analogs, 10(15) CURRENT PHARM. DESIGN. 1713-26 (2004) ("Venkatachalam 2004")

Uesugi et al., A Linear Relationship Between Electronegativity of 2'-Substituents and Conformation of Adenine Nucleosides, 42 TETRAHEDRON LETTERS 4073-76 (1979) ("Uesugi 1979")

Booth et al., Experimental Studies of the Anomeric Effect. Part V1. Ring Inversion Equilibria in Cyclohexane, Tetrahydropyran and Piperidine Rings Substituted by a Carbomethoxy or a Cyano Group, 48(29) TETRAHEDRON 6161-74 (1992) ("Booth 1992")

Transcript of Gerardus J. Boons July 30, 2020 Deposition

Huggins et al., Bond Energies and Polarities, 75(17) J. AM. CHEM. SOC. 4123-26 (1953) ("Huggins 1953")

Ono et al., 2"-Fluoro modified nucleic acids: polymerase-directed synthesis, properties and stability to analysis by matrix-assisted laser desorption/ionization mass spectrometry, 25(22) NUCLEIC ACIDS RESEARCH 4581-88 (1997) ("Ono 1997")

Seley-Radtke et al., The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold, 154 ANTIVIRAL RESEARCH 66-86 (2018) ("Seley-Radtke 2018")

Liu et al., Fluorinated nucleosides: Synthesis and biological implication, 129(9) J. FLUORINE CHEM. 746-66 (2008) ("Liu 2008")

Palusiak et al., Methoxy group as an acceptor of proton in hydrogen bonds, 642 J. MOLECULAR STRUCTURE 97-104 (2002) ("Palusiak 2002")

Ziao et al., Amino and cyano N atoms in competitive situations: which is the best hydrogen-bond acceptor? A crystallographic database investigation, ACTA CRYSTALLOGRAPHICA SECTION B: STRUCTURAL SCI. 850-58 (2001) ("Ziao 2001")

U.S. Patent No. 7,732,453

U.S. Patent No. 8,088,792

U.S. Patent No. 8,999,969

U.S. Patent No. 9,108,953

U.S. Patent No. 9,724,360

U.S. Patent No. 7,432,261 Part 1 of 3

U.S. Patent No. 7,432,261 Part 3 of 3

Tang et al., Controlling DNA Fragmentation in MALDI-MS by Chemical Modification, 69(3) ANALYTICAL CHEM. 302-12 (1997) ("Tang 1997")

Kovacs et al., Hydrogen-Bonding Interactions of the Trifluoromethyl Group:2-Trifluoromethylvinyl Alcohol, 62(6) INT'L J. QUANTUM CHEM. 645-52 (1997) ("Kovacs 1997")

Kirby, A.J., STEREOELECTRONIC EFFECTS 1-23 (Oxford Chemistry Primers, 1996) ("Kirby 1996")

U.S. Patent No. 7,432,261 Part 2 of 3

U.S. Patent No. 9,522,912

U.S. Patent No. 9,573,952

Venkatachalum et al., Effect of change in nucleoside structure on the activation and antiviral activity of phosphoramidate derivatives, 13(18) BIOORGANIC & MED. CHEM. 5408-23 (2005) ("Venkatachalum 2005")

U.S. Patent No. 7,662,819

U.S. Patent No. 8,455,451

U.S. Patent No. 8,912,190

U.S. Patent No. 10,316,049 Part 1 of 2

U.S. Patent No. 10,316,049 Part 2 of 2

Damaraju et al., Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy, 22(47) ONCOGENE 7524-36 (2003) ("Damaraju 2003")

Patent Owner's Response

Granting Patent Owners Motion for Pro Hac Vice Admission of Charles T. Steenburg 37 C.F.R. sec 42.10

Notice of Deposition of Dr. Gerardus Josephus Petrus Henricus Boons

Patent Owner's Unopposed Motion for Pro Hac Vice Admission of Charles T. Steenburg

Declaration of Charles T. Steenburg in Support of Motion for Admission Pro Hac Vice

Petitioner's Fourth Amended Exhibit List

Declaration of Dr. Gerardus Josephus Petrus Henricus Boons

Joint Notice of Stipulation Modifying Scheduling Order

ORDER Granting Petitioner¿¿¿s Unopposed Request to Substitute the Declaration of Victor E. Marquez, Ph.D. 37 C.F.R. ¿¿ 42.5

Ex.3003

Decision Granting Institution of Inter Partes Review

Order Conduct of the Proceeding Scheduling Order

Petitioner's Fifth Amended Mandatory Notices

Petitioner's Updated Power of Attorney

Petitioner's Authorized Table of Supplemental Authority

Patent Owner's Preliminary Response

Patent Owner's Response to Petitioner's Notice of Ranking Petitions

Petitioner's Notice

Conduct of the Proceeding 37 C.F.R. ¿¿ 42.5

ORDER Granting Patent Owner's Motion to Substitute Lead Counsel

Patent Owner's Unopposed Motion to Substitute Lead Counsel

Patent Owner's Second Updated Mandatory Notices

Patent Owner's Updated Power of Attorney

Denying Patent Owner's Motion to Dismiss

Patent Owner's Notice of Denial of Petition for Cert in Regents of the University of Minnesota v. LSI Corp.

PANEL CHANGE ORDER Conduct of the Proceedings 37 C.F.R. ¿¿ 42.5

Transcript of August 20, 2019 Conference Call

Patent Owner's Notice of Filing Transcript of August 20, 2019 Conference Call

Decision - 37 C.F.R. 42.71(b)

Exhibit 3001

Exhibit 3002

Petitioner¿¿¿s Fourth Amended Mandatory Notices

Petitioner's Third Amended Mandatory Notices

Decision Denying Petitioner's Request for Rehearing

Petitioner's Request for Rehearing

Order, Regents of the University of Minnesota v. Gilead Sciences, Inc., Civil Action No. 0:16-cv-02915-SRN-HB, D.I. 139 (D. Minn. Jun. 9, 2017)

January 26, 2018 Email Chain Between Counsel for Petitioner and Counsel for Patent Owner

Stipulation and Proposed Order to Exclude Filings From IPR Proceedings, Regents of the Univ. of Calif. v. St. Jude Medical, LLC (N.D. Cal. Feb. 2, 2018)

Order, Regents of the University of Minnesota v. AT&T Mobility LLC (D. Minn. May 19, 2017)

Gilead's Motion to Stay Pending Inter Partes Review, Regents of the University of Minnesota v. Gilead Sciences, Inc., 17-cv-6056-VC, D.I. 297 (N.D. Cal. Feb. 7, 2018)

Preliminary Amendment, U.S. Patent Application No. 14/229,292, (Mar. 31, 2014)

Stipulated Case Management Statement, Regents of the University of Minnesota v. Gilead Sciences, Inc., 17-cv-6056-VC, D.I. 275 (N.D. Cal. Jan. 2, 2018)

January 26 Email from Counsel for Patent Owner to Board and Counsel for Petitioner

January 28, 2018 Email from Counsel for Petitioner to Board and Counsel for Patent Owner

Petitioner's Third Amended Exhibit List

Conduct of the Proceeding

Petitioner's Second Amended Mandatory Notices

Patent Owner's Updated Mandatory Notices

Transcript of October 24, 2017 Conference Call

Patent Owner Notice of Filing Transcript of October 24, 2017 Conference Call

Decision Petitioner's Motions for Pro Hac Vice Admission of Nevin M. Gewertz, Adam K. Mortara, J. Scott McBride, and Robert S. Schwartz

Order - Conduct of the Proceeding - 37 CFR 42.5

Patent Owner's Reply in Support of Motion to Dismiss

Gilead Sciences, Inc. Opposition to Regents of the University of Minnesota's Motion to Dismiss

EXPUNGED

Patent Owner's Motion to Dismiss

University of Minnesota Charter

University of Minnesota¿¿¿s Consolidated Financial Statements (2015 & 2016)

Gilead Sciences, Inc.¿¿¿s Answer to Plaintiff¿¿¿s Complaint for Patent Infringement

Patent Assignment

Patent Owner's Corrected Certificate of Service

Petitioner's Submission of Transcript

Transcript of Sept. 11, 2017 Conference Call

Petitioner's First Amended Mandatory Notices

Petitioner's Second Amended Exhibit List

Petitioner¿¿¿s Motion For Admission Pro Hac Vice Of Nevin M. Gewertz Under 37 C.F.R. ¿¿ 42.10(c)

Declaration of Nevin M. Gewertz

Petitioner's Motion For Admission Pro Hac Vice Of Adam K. Mortara Under 37 C.F.R. 42.10(c)

Declaration of Adam K. Mortara

Petitioner's Motion For Admission Pro Hac Vice Of J. Scott McBride Under 37 C.F.R. 42.10(c)

Declaration of J. Scott McBride

Petitioner's Motion For Admission Pro Hac Vice Of Robert S. Schwartz Under 37 C.F.R. 42.10(c)

Declaration of Robert S. Schwartz

Petitioner's First Amended Exhibit List

Notice of Accord Filing Date

Patent Owner's Mandatory Notices

Patent Owner's Power of Attorney

File History of U.S. Patent Application No. 14/229,292

U.S. Patent No. 8,815,830

Complaint, Regents of the University of Minnesota v. Gilead Sciences, Inc., Civil Action No. 0:16-cv-02915-SRN-HB (D. Minn., Aug. 29, 2016)

U.S. Patent Application No. 13/753,252

U.S. Patent Application Publication No. 2010/0016251 (Sofia)

Preliminary Amendment, U.S. Patent Application No. 11/721,325 (Jun. 8, 2007)

International Application No. PCT/US2005/044442

U.S. Provisional Application No. 60/634,677

U.S. Patent No. 8,765,935

Calogeropoulou et al., Current Topics in Medicinal Chemistry 2003, 3: 1467-1495

U.S. Patent No. 8,399,428

Declaration of Victor E. Marquez, Ph.D.

Curriculum Vitae of Victor E. Marquez, Ph.D.

Anastasi et al., Current Medicinal Chemistry 2003, 10: 1825-1843

Cahard et al., Mini-Reviews in Medicinal Chemistry 2004, 4: 371-381

Highleyman, "Lodenosine trials stopped due to safety concerns," BETA 12(4): 4 (1999)

Sicardi et al., European Journal of Pharmaceutical Sciences, 22: 25-31 (2004)

Kim et al., Molecular Pharmaceutics, 1: 102-111 (2004)

CenterWatch 2005 FDA Approved Drugs

Yoo et al., J. Med. Chem. 2008, 51: 7593-7601

Pauling, J. Amer. Chem. Soc., 54: 3570-3582 (1932)

Petitioner's Power of Attorney

Petition for Inter Partes Review of U.S. Patent No. 8,815,830